Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

David Giljohann's Biography

David Giljohann, CEO, Exicure

Dr. Giljohann has served as CEO of Exicure since 2013. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including Spherical Nucleic Acid (SNA) constructs. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.

David Giljohann Image

Spherical Nucleic Acids - Activating the Immune System

Monday, 28 October 2019 at 15:15

Add to Calendar ▼2019-10-28 15:15:002019-10-28 16:15:00Europe/LondonSpherical Nucleic Acids - Activating the Immune SystemImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The

Exicure develops spherical nucleic acid (SNA) constructs, which are 3-dimensional arrangements of oligonucleotides where the nucleic acids are densely packed and radially oriented around a nanoparticle. AST-008 is an SNA configuration of a toll-like receptor 9 (TLR9) agonist oligonucleotide, designed to trigger anti-tumor immune responses in patients with cancer. AST-008 is intended to be administered intratumorally in combination with checkpoint inhibitors for the treatment of solid tumors. AST-008 has potent antitumor activity as a monotherapy and synergizes with anti-PD-1 antibody therapy in several preclinical tumor models. Clinical progress with our Phase Ib trial will be discussed.

Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The